• Publications
  • Influence
Migraine prevalence, disease burden, and the need for preventive therapy
The epidemiologic profile of migraine has remained stable in the United States during the past 15 years and more than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it. Expand
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity. Expand
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]
OBJECTIVE To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: Are nonsteroidal anti-inflammatory drugs (NSAIDs)Expand
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials.
Topiramate is generally safe and reasonably well tolerated for the prevention of migraine in adults and occurred more frequently during titration to target doses. Expand
LY293558, a Novel AMPA/GluR5 Antagonist, is Efficacious and Well-Tolerated in Acute Migraine
The efficacy and safety results of LY293558 in this small migraine proof of concept trial, together with supportive preclinical data, provide evidence for a potential role of nonvasoactive AMPA/KA antagonists in treating migraine. Expand
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
This study provides Class 1A evidence that onabotulinumtoxinA treatment reduces headache impact and improves HRQoL and significantly improved all domains of the MSQ v2.1 at 24 weeks. Expand
Evidence‐Based Understanding of Medication‐Overuse Headache: Clinical Implications
The definition of the disorder is clarified, distinguishing it from alternative terminology, and its epidemiology, natural history, and clinical course are described, which indicates patients most at risk of developing medication‐overuse headache need to be identified. Expand
Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse
This study undertakes to examine the effects of Botulinum Toxin Type A in the absence of medication overuse in patients with chronic migraine. Expand
Intranasal Civamide for the Acute Treatment of Migraine Headache
Based upon the results of this study, intranasal civamide may be effective in the acute treatment of migraine headache and should be substantially more effective for prophylaxis than acutereatment of migraine. Expand